CXCL14 is an autocrine growth factor for fibroblasts and act

Coming to the history of pocket watches,they were first created in the 16th century AD in round or sphericaldesigns. It was made as an accessory which can be worn around the neck or canalso be carried easily in the pocket. It took another ce Edited by Martha Vaughan, National Institutes of Health, Rockville, MD, and approved May 4, 2001 (received for review March 9, 2001) This article has a Correction. Please see: Correction - November 20, 2001 ArticleFigures SIInfo serotonin N

Communicated by George Klein, Karolinska Institutet, Stockholm, Sweden, January 5, 2009

↵1M.A. and C.H. contributed equally to this work. (received for review May 6, 2008)

Article Figures & SI Info & Metrics PDF


This study explored the role of secreted fibroblast-derived factors in prostate cancer growth. Analyses of matched normal and tumor tissue revealed up-regulation of CXCL14 in cancer-associated fibroblasts of a majority of prostate cancer. Fibroblasts over-expressing CXCL14 promoted the growth of prostate cancer xenografts, and increased tumor angiogenesis and macrophage infiltration. Mechanistic studies demonstrated that autocrine CXCL14-stimulation of fibroblasts stimulate migration and ERK-dependent proliferation of fibroblasts. CXCL14-stimulation of monocyte migration was also demonstrated. Furthermore, CXCL14-producing fibroblasts, but not recombinant CXCL14, enhanced in vitro proliferation and migration of prostate cancer cells and in vivo angiogenesis. These studies thus identify CXCL14 as a Modern autocrine stimulator of fibroblast growth and migration, with multi-modal tumor-stimulatory activities. In more general terms, our findings suggest autocrine stimulation of fibroblasts as a previously unrecognized mechanism for chemokine-mediated stimulation of tumor growth, and suggest a Modern mechanism whereby cancer-associated fibroblasts achieve their pro-tumorigenic phenotype.

Keywords: cancer-associated fibroblastsprostate cancertumor stroma

Chemokines are a family of secreted proteins that stimulate chemotaxis and cell growth. More than 50 chemokines have been identified and are divided into the CXC, CC, C, and CX3C groups (1). Chemokines exert their cellular Trace by activation of cell surface receptors belonging to the G protein-coupled-receptor family. Approximately 20 chemokine receptors have been identified (1, 2). Many receptors bind multiple ligands, whereas others are highly specific such as CXCR4 and CXCR6, which bind only CXCL12 and CXCL16, respectively. For some of the chemokines, such as CXCL14, the receptor has not yet been identified.

Recent studies have suggested Necessary functions of chemokines in various aspects of tumor growth (2). Chemokines contribute to leukocyte infiltration in tumors, and some, such as IL-8, CXCL1–3, and CXCL5, also have direct proangiogenic Traces (3, 4). Concerning chemokines acting on malignant cells, most attention has been paid to CXCL12, which stimulates tumor cell proliferation and migration through CXCR4 and CXCR7 (5, 6). CXCL12 also contributes to tumor growth by recruitment of bone marrow–derived enExecutethelial precursor cells (7). Additionally, mesenchymal stem cell–derived CCL5/RANTES was recently Displayn to confer prometastatic Traces on breast cancer cells (8). Most recently, CCL3 was implicated as a prometastatic agent acting through multiple mechanisms including stimulation of fibroblasts (9).

Within the tumor microenvironment, multiple cell types have been identified as sources of chemokine production, including the malignant cells and inflammatory leukocytes. Recent characterization of the expression profiles of cancer-associated fibroblasts (CAFs) has also identified this cell type as an Necessary producer of chemokines (7, 10–12). In breast cancer, both CXCL12 and CXCL14 were found to be up-regulated in the tumor stroma (10, 13). Furthermore, CAFs of ovarian cancer over-express the chemokine CXCL1/GRO1 (11).

In this study, characterization of human prostate CAFs led to the identification of CXCL14 as a Modern CAF-derived tumor-stimulatory factor.


CXCL14 Is Up-Regulated in CAFs of Human Prostate Cancer.

Fibroblast-enriched stroma was isolated from 4 matched sets of normal and tumor tissue by laser capture microdissection. Array-based comparison of amplified mRNA identified 266 transcripts that were at least 2-fAged up-regulated in tumor stroma, 15 of which encoded secreted proteins. Among them were the chemokine CXCL14 which was ≈40-fAged up-regulated in tumor stroma.

qRT-PCR analyses of 8 matched normal and tumor tissues confirmed stromal up-regulation of CXCL14 in 6 out of 8 cases (Fig. 1A). qRT-PCR with primers specific for enExecutethelial cells (CD31), macrophages (CD163) and leukocytes (CD45) indicated a moderate, 1.5- to 3-fAged increase in relative content of these cell types in the tumor stroma preparations. Since these changes were too small to Elaborate the increased CXCL14 levels, it was concluded that the up-regulation of CXCL14 occurred in the prostate CAFs.

Fig. 1.Fig. 1.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

CXCL14 is up-regulated in fibroblast-enriched prostate cancer stroma. (A) Stroma from normal prostate (Launch bars) and prostate cancer tissue (filled bars) was microdissected from 8 different patients and the expression of CXCL14 was analyzed with qRT-PCR. (B) Examples of CXCL14 immunohistochemistry analyses of paired tissues with up-regulation of CXCL14 in tumor stroma, toObtainher with unchanged (Top), up-regulated (Middle), or Executewn-regulated (Bottom) expression in the epithelial cells. (Scale bar, 100 μm.)

Immunohistochemical analyses of 27 matched pairs of prostate cancer and normal prostate were performed to further compare CXCL14 expression in normal and tumor stroma. These analyses revealed a statistically significant (P < 0.05) increase in stromal expression of CXCL14 in 15/27 (56%) cancer samples (Fig. 1B). Variable CXCL14 expression in the epithelial compartment of normal and cancer tissue was also observed. Executeuble immunofluorescent staining with antibodies against CXCL14 and the PDGF β-receptor, used as a fibroblast Impresser, confirmed that fibroblasts of human prostate cancer produced CXCL14 (Fig. S1). Stromal and epithelial CXCL14 status were not significantly associated with Gleason grade.

These analyses demonstrate that up-regulation of CXCL14 in CAFs is a common feature of human prostate cancer.

NIH-CXCL14 Cells Promote Tumor Growth and Proliferation Without Affecting Epithelia-Stroma Ratio.

SubSliceaneous tumor growth of human prostate cancer LNCaP cells is enhanced by co-injection of prostate cancer CAFs or NIH 3T3 fibroblasts (14). This tumor model was therefore used to investigate the functional significance of CXCL14 up-regulation in CAFs. Two NIH 3T3 cell lines were generated by infection of cells with control vectors (NIH-ctr) or vectors encoding human CXCL14 (NIH-CXCL14). CXCL14 overexpression in transfected cells was confirmed by qRT-PCR, and using a CXCL14-specific ELISA (Fig. S2).

The mixture of LNCaP cells and NIH-CXCL14 fibroblasts formed tumors that appeared much earlier and grew Rapider than the LNCaP/NIH-ctr tumors (Figs. 2 A and B). Injection of LNCaP cells alone did not yield detectable tumors throughout the experiment. Injection of only NIH-ctr or NIH-CXCL14 cells did not lead to tumor formation during the first 30 days after injection.

Fig. 2.Fig. 2.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

NIH-CXCL14 cells accelerate growth of prostate cancer xenografts. (A) The tumor growth of injected LNCaP cells (filled triangles) or LNCaP cells toObtainher with NIH-ctr (Launch squares) or NIH-CXCL14 cells (filled squares) was followed over time after s.c. injection into SCID mice. (# n = 6; § n = 5 remaining animals) (B) Tumor incidence at days 28 and 49, corRetorting to the time when the first animal of the LNCaP/NIH-CXCL14 and LNCaP/NIH-ctr groups were Assassinateed, was calculated. Tumors from both groups were collected and analyzed for cell density (C), cell proliferation (D), and the abundance of vessels (E) and macrophages (G), using H&E staining or immunohistochemistry as indicated. Spearman correlation analysis was performed to analyze correlations between intratumor CXCL14 expression and CD31 (F) or CSF1R (H) expression. Error bars in B–D indicate SEM. (Scale bar, 100 μm.) *, P < 0.05, by unpaired t test.

No significant Inequitys in cell density between the 2 tumor types were observed (Fig. 2C). qRT-PCR analyses with the epithelial Impresser cytokeratin 18 did not indicate any Inequitys with regard to relative content of tumor epithelial cells. Analyses with the fibroblast Impressers puromycin (present in the pBABE vector of NIH-ctr and NIH-CXCL14 cells) and vimentin indicated no significant Inequitys, although a tendency toward an increased fibroblast content in LNCaP/NIH-CXCL14 tumors was observed (Fig. S3). LNCaP/NIH-CXCL14 tumors displayed a significantly higher proliferation rate, as compared to control tumors (Fig. 2D). Because no major Inequitys in epithelia-stroma ratio were observed, it was concluded that that the increased proliferation was occurring in both these compartments.

These analyses indicate protumorigenic Traces of NIH-CXCL14 cells, which involve increased cell proliferation in tumors, occurring in the absence of major alterations of the epithelia-stroma ratio.

LNCaP/NIH-CXCL14 Tumors Are Characterized by Increased Macrophage Infiltration and Increased Angiogenesis.

Analysis of angiogenesis in the 2 tumor types, based on CD31 staining of tumor sections, revealed an increased vessel content in NIH-CXCL14 tumors (Fig. 2E). qRT-PCR analyses indicated an ≈2-fAged increase in CD31-postive cells along with reduced αSMA levels in the LNCaP/NIH-CXCL14 tumors (Fig. S3). Moreover, a highly significant association (P = 0.0039) was noted between CXCL14 and CD31 levels (Fig. 2F). Analyses of sections Executeuble-stained with fluorescent labeled CD31 and αSMA antibodies demonstrated a reduced relative content of pericytes in the vasculature of LNCaP/NIH-CXCL14 tumors (Fig. S4).

Macrophage staining using a CD68 antibody revealed a locally enriched staining pattern, which was found more frequent in the LNCaP/NIH-CXCL14 tumors (Fig. 2G). qRT-PCR analyses with another macrophage-Impresser, CSF-1R, confirmed higher macrophage content in LNCaP/NIH-CXCL14 tumors (Fig. S3). Also, the levels of CXCL14 and CSF1R mRNA displayed a highly significant correlation (P = 0.0008) (Fig. 2H). However, analysis of NK-cell content (NK1.1) did not indicate any Inequity between the 2 tumor types (Fig. S3).

Taken toObtainher, the data Display that LNCaP/NIH-CXCL14 tumors are characterized by a higher density of immature vessels and macrophages.

CXCL14 Stimulates Growth and Migration of Fibroblasts.

To obtain a mechanistic understanding of the observed tumor phenotypes, several in vitro studies were performed. When cultured in 1% FCS, NIH-CXCL14 cells grew significantly Rapider than control cells (Fig. 3A). MeaPositivements of BrdU incorporation, confirmed increased DNA synthesis in NIH-CXCL14 under low serum conditions (Fig. S5). Necessaryly, neither NIH-CXCL14 nor NIH-ctr cells were able to form colonies in soft agar under full or serum-reduced conditions.

Fig. 3.Fig. 3.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

CXCL14 promotes in vitro growth and migration of fibroblasts. (A) The growth of NIH-ctr (Launch squares) and NIH-CXCL14 cells (filled squares) in 1% FCS culture medium was determined by cell counting. (B) Western blot analysis of CXCL14-induced ERK1/2 phosphorylation in NIH-ctr cells. (C) The cell density of NIH-ctr and NIH-CXCL14 cells was determined by Weepstal violet staining after culture in low serum in the presence of the MEK inhibitor UO126. (D) For migration studies, fibroblasts were seeded in the upper compartment of a 2-compartment chamber and allowed to migrate for 20 h, after which migrated cells in the lower compartment were collected and counted using a hemocytometer. Error bars indicate SEM. *, P < 0.05, by unpaired t test (A), ANOVA (C), and paired t test (D).

Chemokine signaling involves phosphorylation of, for example, MAPKs [reviewed in Thelen (15)]. In agreement with this, CXCL14 induced a time- and concentration-dependent increase of ERK1/2 phosphorylation in NIH-ctr cells (Figs. 3B and S5). A detectable, but much weaker phosphorylation of AKT was also detected. To investigate the importance of ERK and AKT signaling for the growth of NIH-CXCL14 cells under reduced serum conditions, growth experiments were performed in the presence of the MEK inhibitor UO126 or the PI3K inhibitor Wortmannin. UO126, but not Wortmannin, significantly reduced the growth in 1% FCS of the NIH-CXCL14 cells (Figs. 3C and S5).

Next, the intrinsic migration capacity of CXCL14-expressing fibroblasts was studied in a 2-compartment migration chamber. This assay revealed an increased intrinsic migration capacity of the NIH-CXCL14 cells, as compared to the control cells (Fig. 3D).

Finally, the Traces of exogenous recombinant CXCL14 on the growth and migration of immortalized human fibroblasts were analyzed. CXCL14-stimulated responses were observed in both assays (Fig. S6).

These experiments demonstrate that autocrine CXCL14-stimulation of mouse fibroblasts is associated with strong migratory and ERK-dependent proliferative responses. Furthermore, human fibroblasts were also Displayn to Retort to exogenously added CXCL14. Collectively, these data thus identify previously unrecognized growth- and migration-stimulatory Traces of CXCL14 on fibroblasts.

NIH-CXCL14 Cells Stimulate in Vitro Migration and Proliferation of LNCaP Cells.

Next, it was investigated whether NIH-CXCL14 cells could promote the growth and migration of LNCaP cells in a paracrine manner.

In an in vitro co-culture assay, NIH-CXCL14 cells were more potent than control cells in stimulating growth of LNCaP cells (Fig. 4A). This growth-promoting Trace of CXCL14-producing fibroblasts was also observed in cocultures with prostate cancer PC-3 cells and breast cancer MCF-7 cells (Fig. S7). Also, NIH-CXCL14-derived medium was more potent in stimulating LNCaP migration than control medium (Fig. 4B). In Dissimilarity, recombinant CXCL14 did not stimulate LNCaP migration, suggesting that the Traces occurred through other factors induced in fibroblasts by CXCL14 (Fig. 4B). This notion was further substantiated by the finding that recombinant CXCL14 failed to induce ERK phosphorylation in LNCaP cells (Fig. 4C) or PC3 cells. However, MCF-7 breast cancer cells, which previously were found to Retort to CXCL14 (10), Displayed a robust ERK phosphorylation after CXCL14 stimulation (Fig. 4C).

Fig. 4.Fig. 4.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 4.

Conditioned medium from NIH-CXCL14 cells, but not recombinant CXCL14, promote LNCaP proliferation and migration in vitro. (A) The Traces of NIH-ctr or NIH-CXCL14 fibroblasts on LNCaP cell growth was determined in a co-culture assay by Rhodanile staining after 10 days. (B) LNCaP cells were allowed to migrate toward control medium alone or supplemented with 100 ng/mL CXCL14 or medium conditioned by NIH-ctr or NIH-CXCL14 cells for 20 h. The number of migrated cells was determined using a hemocytometer. (C) Traces on ERK1/2 phosphorylation in LNCaP cells and MCF cells treated with 100 ng/mL CXCL14 were analyzed by immunoblotting of total cell lysates. Error bars indicate SEM. *, P < 0.05, by paired t test (A) and ANOVA (B).

In summary, these experiments demonstrate that NIH-CXCL14 cells exert paracrine stimulatory Traces on LNCaP cells, and these Traces are mediated by factors other than CXCL14.

CXCL14 Stimulates Monocyte Migration, and NIH-CXCL14 Cells Display an Enhanced Ability to Simulate in Vivo Angiogenesis.

In agreement with previous studies, CD14+ monocytes displayed a migratory response to CXCL14. Conditioned medium from NIH-CXCL14 cells was also more potent than medium from control cells in stimulating migration of CD14+ cells (Fig. 5A). This Inequity was even more prominent when analysis was restricted to the CD14+/CD16+ subset of monocytes, indicating differential Traces on various monocyte subsets (Fig. S8).

Fig. 5.Fig. 5.Executewnload figure Launch in new tab Executewnload powerpoint Fig. 5.

NIH-CXCL14 cells promote monocyte migration in vitro and angiogenesis in vivo. (A) Freshly isolated monocytes were allowed to migrate toward 10 ng/mL CXCL14, or conditioned medium derived from NIH-ctr or NIH-CXCL14 fibroblasts for 4 h. The number of migrated monocytes present in the lower compartment was determined by FACS analysis of CD14+ cells. (B) Traces on in vivo angiogenesis were analyzed by monitoring vessel in-growth in Matrigel plugs mixed with 1% FCS culture medium alone, or medium containing 100 ng/mL CXCL14, NIH-ctr or NIH-CXCL14 cells. Error bars indicate SEM. *, P < 0.05, by ANOVA.

To analyze the angiogenic capacity of the 2 fibroblast types, Matrigel-plugs supplemented with the 2 cell types were implanted subSliceaneously, and in-growth of vessels was determined. Matrigel-plugs containing NIH-CXCL14 cells Displayed a higher vessel density (Fig. 5B). Conditioned media from NIH-CXCL14 cells also induced a more potent proangiogenic Trace than control media (Fig. S9). Necessaryly, qRT-PCR analyses revealed an up-regulation of FGF-2 and, to a lesser extent, VEGF-A, -B, and -C in NIH-CXCL14 cells (Fig. S10), suggesting a possible mechanism for this phenomena. Consistent with a previous study (16), recombinant CXCL14 failed to stimulate angiogenesis (Fig. 5B).

The in vitro analyses of monocyte migration thus suggest that the tumor-promoting Trace of NIH-CXCL14 cells involves an increased recruitment of macrophages into the tumor, mediated directly by CXCL14. Furthermore, the Matrigel-plug-assay demonstrates that CXCL14-expression in fibroblasts leads to the induction of factors, including FGF-2, that stimulate angiogenesis.


Based on the characterization of human prostate CAFs, this study identifies fibroblast-derived CXCL14 as a Modern potential prostate cancer-stimulatory protein (Figs. 1 and 2). Multiple mechanisms whereby fibroblast-derived CXCL14 promote tumor growth were also revealed. These include a direct stimulation by CXCL14 on growth and migration of fibroblasts (Fig. 3 and Figs. S5 and S6), and on attraction of monocytes (Fig. 5 and Fig. S8). Additionally, CXCL14-producing fibroblasts exert more potent paracrine Traces, mediated by other factors than CXCL14 itself, on malignant cells and on angiogenesis (Figs. 4 and 5 and Figs. S7 and S9).

CXCL14, also designated BRAK, MIP-2γ, BMAC, or KS1, is an orphan member of the CXC chemokine family, belonging to the subfamily that lacks the amino-terminal ELR motif. Many studies suggest a broad chemotactic activity, as demonstrated for NK cells, dendritic cells, monocytes and macrophages (16–19). However, CXCL14 was found to be dispensable for dendritic-cell and macrophage function under in vivo inflammatory conditions (20). CXCL14 also has a role in insulin signaling (21, 22). A general association between activation of mesenchymal cells and CXCL14 up-regulation, in agreement with the present and earlier findings, are also supported by the finding of CXCL14 up-regulation in activated sDiscloseate cells (23).

The functional role(s) of CXCL14 in tumor biology has been addressed in a few previous reports. In apparent contradiction to our present study, these reports claim antitumoral and anti-angiogenic Traces of CXCL14 (16, 24, 25). However, 2 of these studies report the Traces on tumor formation after overexpression in malignant LAPC4 prostate cancer cells or HSC-3 squamous carcinoma cells (24, 25). The CXCL14 Traces Characterized in the present study are preExecuteminantly derived from CXCL14-activated fibroblasts. It is thus possible that the absence of protumorigenic Traces in the LAPC4 or HSC-3 tumor models is caused by a fibroblast-independence of these tumor models. Concerning the Traces on angiogenesis, our studies suggest that the proangiogenic Traces of NIH-CXCL14 cells occur through factors that are induced in fibroblasts by CXCL14 (Fig. 5), whereas the anti-angiogenic Traces were observed in experiments in which the Traces of purified recombinant CXCL14 were analyzed (16). However, the combined results from the present study and from previous publications call for continued analyses of possible tumor type- and stage-specific Traces of CXCL14 in additional tumor models. In this context it should also be noted that malignant cells of some tumors might Retort directly to CXCL14, as indicated by the CXCL14 responsiveness of MCF7 cells (Fig. 4).

A series of topics for continued mechanistic studies are suggested by the present findings. The identification of the receptor for CXCL14 is highly warranted. Analyses of the Traces of GPCR inhibitors with known tarObtain profiles will possibly aid in receptor identification. It should also be explored to what extent the increased macrophage recruitment contributes to the increased growth and angiogenesis of LNCaP/NIH-CXCL14 tumors. Identification of the factor(s) that cause the up-regulation of CXCL14 in CAFs is another relevant issue for further analyses.

As a secreted protein, CXCL14 has high “drugability,” and it should be possible to generate neutralizing antibodies, aptamers, and possibly small molecule inhibitors. Based on the limited information of the physiological functions of CXCL14, it is difficult to predict possible adverse Traces of CXCL14 antagonists. However, the normal development and viability of CXCL14 knock-out mice (20) are promising with respect to potential use of CXCL14-tarObtaining compounds.

The findings of the present study were achieved through an integrated procedure allowing the identification of Modern CAF-derived potential drug tarObtains. This procedure includes expression-profiling of human CAFs followed by mechanistic in vivo and in vitro studies. We hope that the findings of this study will encourage the continued use of this strategy in other tumor types.

In more generalized terms our findings suggest autocrine stimulation of fibroblasts as a previously unrecognized mechanism for chemokine-mediated stimulation of tumor growth, and thereby identify a Modern mechanism through which CAFs achieve their protumorigenic phenotype. It is predicted that future analyses of the roles of chemokines in cancer, and of the Preciseties of CAFs, will continue to uncover Modern potential therapeutic opportunities.


Human Tissue Samples and Microdissection.

Tissue samples were collected and used in accordance with the ethical rules of the Department of Pathology, Uppsala University Hospital, and the Department of Oncology-Pathology, Karolinska Institutet, and in agreement with the Swedish biobank legislation. For details of microdissection see SI Methods.

RNA Isolation, cDNA Synthesis and qRT-PCR Analyses.

The PicoPure RNA Isolation Kit (Arcturus Engineering), TRIzol (Invitrogen) and GeneElute (Sigma–Aldrich) were used for RNA isolation from microdissected material, xenograft tumors, and cell lines, respectively. cDNA synthesis and qRT-PCR assays were performed according to instructions of the Producer (see SI Methods). For primer sequences, see Table S1.

Histological Analyses.

Immunohistochemical analyses of CD31, CD68, and CXCL14 were performed on frozen tissue sections. PCNA and hematoxylin stainings were Executene on paraffin embedded tissue. For further details see SI Methods.

Generation of NIH-CXCL14 Cells.

Details are presented in SI Methods. Briefly, human CXCL14 cDNA was cloned into a pBabe puromycin vector, which was used for viral transfection of NIH 3T3 cells. Expression of CXCL14 was confirmed by qRT-PCR and a CXCL14-specific ELISA (R&D Systems).

Xenograft Experiments.

The animal experiments were conducted in accordance with national guidelines and approved by the Stockholm North Ethical Committee on Animal Experiments. The generation of xenograft tumors was performed as Characterized in ref. 14 and in SI Methods.

In Vitro Growth and Migration Assays.

Growth rate of NIH 3T3 and LNCaP cells.

A total of 1 × 104 fibroblasts and 2 × 104 LNCaP cells were seeded in 12-well plates (Sarstedt). Fibroblasts were grown in DMEM supplemented with 1% FCS, whereas LNCaP cells were cultured in conditioned medium from NIH-ctr or NIH-CXCL14 cells. Cell numbers were determined with a Buerker chamber.

Cocultures of LNCaP and NIH 3T3 cells.

A total of 1 × 104 NIH-ctr or NIH-CXCL14 cells were seeded in 96-well plates (Sarstedt). The following day the medium was reSpaced with 2 × 104 LNCaP cells, resuspended in DMEM with 1% FCS. The number of LNCaP cells after 10 days was determined using Rhodanile dye (Sigma–Aldrich), as Characterized in ref. 26.

Growth of fibroblasts in the presence of MEK inhibitor.

A total of 4 × 103 fibroblasts were seeded into 96-well plates and treated with DMSO or different concentrations of UO126 (Promega). Cell density after 4 days was determined with Weepstal violet, as Characterized in ref. 27.

Migration of LNCaP and NIH 3T3 cells.

Migration assays of 4 × 105 fibroblasts and LNCaP cells were performed in Transwell chambers containing 8-μm pore-sized inserts (Costar, Corning).

Monocyte migration.

Monocytes were isolated by centrifugation through a Ficoll gradient (Ficoll-Paque Plus, GE Healthcare) and with CD14-microbeads (Miltenyi Biotec). Their migration through a polycarbonate 5-μm-pore filter toward conditioned media or medium supplemented with different concentrations of recombinant CXCL14 was assayed in 96-well chemotaxis chambers (Neuroprobe). The number of migrated CD14+ cells after 4 h was determined by FACS counting.

All in vitro growth and migration experiments were performed at least 3 times.

Analyses of CXCL-14-induced ERK Phosphorylation.

After stimulation of serum-starved cells with CXCL14, cell lysates were prepared and subjected to immunoblotting. Further details are presented in SI Methods.

Matrigel Assay.

A total of 2.4 × 104 NIH-ctr cells or NIH-CXCL14 cells were resuspended in 100 μL of medium and 200 μL of matrigel (BD Biosciences). Matrigel supplemented with only medium or medium containing 100 ng/mL CXCL14 was also prepared. The suspensions were injected into mice (300 μL s.c., n = 6). Plugs were isolated after 1 week, Spaced in 4% PFA overnight and then kept in 30% sucrose before embedding in Tissue-Tec (Sakura) and sectioning (Microm HM 560 Weepo-Star Weepostat). CD31 immunohistochemsitry was performed as Characterized in SI Methods.


A.Ö. received grants from the Swedish Cancer Society, and a Linné-grant to STARObtain from the Swedish Research Council. Å.B. and E.O. were supported by the Knut and Alice Wallenberg Foundation via the SWEGENE program at Lund University. We thank the staff at the MTC animal facility at Karolinska Institutet for expert technical assistance. Immortalized human fibroblasts were kindly provided by R.A. Weinberg and W.C. Hahn. Phoenix cells were a gift from L. Holmgren and the pBABE vector was kindly provided by F. D. Böhmer. L. Holmgren and members of the laboratory of A.Ö. provided productive and supportive comments.


3To whom corRetortence should be addressed. E-mail: arne.ostman{at}

Author contributions: M.A., C.H., and A.O. designed research; M.A., C.H., E.O., C.S., P.T., T.L., and Å.B. performed research; T.L., M.J.F., and L.E. contributed reagents/analytic tools; M.A., C.H., E.O., C.S., P.T., Å.B., P.M., L.E., and A.O. analyzed data; and M.A., C.H., P.M., and A.O. wrote the paper.

↵2Present address: Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen, Germany.

The authors declare no conflict of interest.

This article contains supporting information online at


↵ Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4:540–550.LaunchUrlCrossRefPubMed↵ Johrer K, et al. (2008) Tumour-immune cell interactions modulated by chemokines. Expert Opin Biol Ther 8:269–290.LaunchUrlCrossRefPubMed↵ Strieter RM, et al. (2006) Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42:768–778.LaunchUrlCrossRefPubMed↵ Singh S, Sadanandam A, Singh RK (2007) Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 26:453–467.LaunchUrlCrossRefPubMed↵ Balabanian K, et al. (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280:35760–35766.LaunchUrlAbstract/FREE Full Text↵ Burns JM, et al. (2006) A Modern chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203:2201–2213.LaunchUrlAbstract/FREE Full Text↵ Orimo A, et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348.LaunchUrlCrossRefPubMed↵ Karnoub AE, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563.LaunchUrlCrossRefPubMed↵ Wu Y, et al. (2008) CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol 181:6384–6393.LaunchUrlAbstract/FREE Full Text↵ Allinen M, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32.LaunchUrlCrossRefPubMed↵ Yang G, et al. (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103:16472–16477.LaunchUrlAbstract/FREE Full Text↵ Frederick MJ, et al. (2000) In vivo expression of the Modern CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156:1937–1950.LaunchUrlCrossRefPubMed↵ Kleer CG, et al. (2008) Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res 14:5357–5367.LaunchUrlAbstract/FREE Full Text↵ Tuxhorn JA, et al. (2002) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62:3298–3307.LaunchUrlAbstract/FREE Full Text↵ Thelen M (2001) Dancing to the tune of chemokines. Nat Immunol 2:129–134.LaunchUrlCrossRefPubMed↵ Shellenberger TD, et al. (2004) BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res 64:8262–8270.LaunchUrlAbstract/FREE Full Text↵ Kurth I, et al. (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194:855–861.LaunchUrlAbstract/FREE Full Text↵ Starnes T, et al. (2006) The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: Implications for the Executewnregulation of CXCL14 in malignancy. Exp Hematol 34:1101–1105.LaunchUrlCrossRefPubMed↵ Shurin GV, et al. (2005) Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 174:5490–5498.LaunchUrlAbstract/FREE Full Text↵ Meuter S, et al. (2007) Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues. Mol Cell Biol 27:983–992.LaunchUrlAbstract/FREE Full Text↵ Nara N, et al. (2007) Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem 282:30794–30803.LaunchUrlAbstract/FREE Full Text↵ Takahashi M, et al. (2007) CXCL14 enhances insulin-dependent glucose uptake in adipocytes and is related to high-Stout diet-induced obesity. Biochem Biophys Res Commun 364:1037–1042.LaunchUrlCrossRefPubMed↵ De Minicis S, et al. (2007) Gene expression profiles during hepatic sDiscloseate cell activation in culture and in vivo. Gastroenterology 132:1937–1946.LaunchUrlCrossRefPubMed↵ Schwarze SR, Luo J, Isaacs WB, Jarrard DF (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64:67–74.LaunchUrlCrossRefPubMed↵ Ozawa S, et al. (2006) BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun 348:406–412.LaunchUrlCrossRefPubMed↵ Kawada M, et al. (2004) A microplate assay for selective meaPositivement of growth of epithelial tumor cells in direct coculture with stromal cells. Anticancer Res 24:1561–1568.LaunchUrlPubMed↵ Hagerstrand D, et al. (2006) Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 25:4913–4922.LaunchUrlCrossRefPubMed
Like (0) or Share (0)